TrialHuman vaccines & immunotherapeutics2026

Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.

Zourab Bebia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.